Summary: High cholesterol level is one of the major, modifiable cardiovascular risk factor. One of the most important elements in the management of patients with dyslipidaemia is to estimate and stratify cardiovascular risk and determine goals of low-density lipoprotein cholesterol (LDL-C) levels. Statins are basic recommended drugs in management of dyslipidaemia. If the goals are not achieved with the maximum tolerated dose of statin, combination with ezetimibe is recommended. Combined therapy in most cases is sufficient in achieving desired low-density lipoprotein cholesterol (LDL-C) levels and improving the outcomes in the long-term observation.